Dokument: Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
| Titel: | Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=71470 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20251121-132816-2 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Räuber, Saskia [Autor] Korsen, Melanie [Autor] Huntemann, Niklas [Autor] Rolfes, Leoni [Autor] Müntefering, Thomas [Autor] Dobelmann, Vera [Autor] Hermann, Alexander M. [Autor] Kölsche, Tristan [Autor] von Wnuck Lipinski, Karin [Autor] Schroeter, Christina [Autor] | |||||||
| Dateien: |
| |||||||
| Beschreibung: | Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included in clinical trials and real-world clinical data point to an attenuated immune response to SARS-CoV-2 vaccines among patients with multiple sclerosis (MS) receiving immunomodulatory therapies.
Methods We performed a retrospective study including 59 ocrelizumab (OCR)-treated patients with MS who received SARS-CoV-2 vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters and peripheral immune cell profiles were measured prior to the first (baseline) and at a median of 4 weeks after the second vaccine dose (follow-up). Moreover, the SARS-CoV-2-specific T cell response and peripheral B cell subsets were analysed at follow-up. Finally, vaccination-related adverse events were assessed. Results After vaccination, we found anti-SARS-CoV-2(S) antibodies in 27.1% and a SARS-CoV-2-specific T cell response in 92.7% of MS cases. T cell-mediated interferon (IFN)-γ release was more pronounced in patients without anti-SARS-CoV-2(S) antibodies. Antibody titres positively correlated with peripheral B cell counts, time since last infusion and total IgM levels. They negatively correlated with the number of previous infusion cycles. Peripheral plasma cells were increased in antibody-positive patients. A positive correlation between T cell response and peripheral lymphocyte counts was observed. Moreover, IFN-γ release was negatively correlated with the time since the last infusion. Conclusion In OCR-treated patients with MS, the humoral immune response to SARS-CoV-2 vaccination is attenuated while the T cell response is preserved. However, it is still unclear whether T or B cell-mediated immunity is required for effective clinical protection. Nonetheless, given the long-lasting clinical effects of OCR, monitoring of peripheral B cell counts could facilitate individualised treatment regimens and might be used to identify the optimal time to vaccinate. | |||||||
| Rechtliche Vermerke: | Originalveröfffentlichung:
Räuber, S., Korsen, M., Huntemann, N., Rolfes, L., Müntefering, T., Dobelmann, V., Hermann, A. M., Kölsche, T., von Wnuck Lipinski, K., Schroeter, C. B., Nelke, C., Regner-Nelke, L., Ingwersen, J., Pawlitzki, M., Teegen, B., Barnett, M. H., Hartung, H.-P., Aktas, O., Albrecht, P., … Kremer, D. (2022). Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 93(9), 978–985. https://doi.org/10.1136/jnnp-2021-328197 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 21.11.2025 | |||||||
| Dateien geändert am: | 21.11.2025 |
